Company: JUNS
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001641172-25-024684
Chunk: 31

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-08-19
Form: 10-Q
Item: Item 2
Chunk 31
---
The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited
condensed financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial information
and related notes included in our Annual Report on Form 10-K for fiscal 2024, which was filed with the Securities and Exchange Commission,
or the SEC, on March 28, 2025, or the Annual Report.

Special
Note Regarding Forward-Looking Statements

All
statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including, without limitation, statements
under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s
financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements.
When used in this Quarterly Report on Form 10-Q, words such as “anticipate,” “believe,” “estimate,”
“expect,” “intend” and similar expressions, as they relate to us or the Company’s management, identify
forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and
information currently available to, the Company’s management. Actual results could differ materially from those contemplated by
the forward-looking statements as a result of certain factors detailed in our filings with the SEC.

The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with the financial
statements and the notes thereto contained elsewhere in this Quarterly Report on Form 10-Q. Certain information contained in the discussion
and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Unless the context otherwise requires,
“JNS,” “we,” “us,” “our,” or the “Company” refers to Jupiter Neurosciences,
Inc.

Business
Overview

Jupiter
Neurosciences, Inc. (the “Company,” “we” or “us”) is a clinical stage research and development pharmaceutical
company located in Jupiter, Florida. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders
and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both
efforts are powered by JOTROL™, Jupiter’s proprietary, enhanced resveratrol formulation that has demonstrated significantly
improved bioavailability. The Company’s prescription pipeline is focused broadly on CNS disorders, presently with